Department of Endocrinology and Isotope Therapy, Military Institute of Medicine, Warsaw, Poland.
Department of Internal Diseases, Nephrology and Dialysis, Military Institute of Medicine, Warsaw, Poland.
Nucl Med Rev Cent East Eur. 2022;25(1):54-61. doi: 10.5603/NMR.a2022.0016.
Neuroendocrine neoplasms (NENs) are a heterogeneous group of tumors originating from neuroendocrine cells spread throughout the body, forming the so-called diffuse endocrine system. The gold standard in treating unresectable or disseminated, progressive, and well-differentiated NENs is therapy with radiolabeled somatostatin analogs (peptide receptor radionuclide therapy - PRRT). PRRT is a method based on peptides combined with beta-emitting radionuclides. The study aimed to assess the early and long-term liver complications after administration of Lutetium-177 or Lutetium-177 combined with Yttrium-90. We enrolled 27 patients treated with [177Lu]Lu-DOTATATE with an activity of 7.4 GBq (200 mCi) and 9 patients received the tandem treatment [90Y]Y-DOTATATE + [177Lu]Lu-DOTATATE with an activity of 3.7 GBq (50 mCi + 50 mCi). In the assessment of early as well as long-term complications, no significant effect of the applied treatment on the parameters of liver injury was found. Regarding liver function PRRT was a safe treatment for patients with highly or moderately differentiated, unresectable, or diffuse NENs.
神经内分泌肿瘤（NENs）是一组起源于神经内分泌细胞的异质性肿瘤，这些细胞分布在全身，形成所谓的弥散内分泌系统。治疗不可切除或播散性、进行性和高分化 NENs 的金标准是用放射性标记的生长抑素类似物（肽受体放射性核素治疗 - PRRT）治疗。PRRT 是一种基于与β发射放射性核素结合的肽的方法。本研究旨在评估给予镥-177 或镥-177 联合钇-90 后的早期和长期肝脏并发症。我们招募了 27 名接受[177Lu]Lu-DOTATATE 治疗的患者，活性为 7.4GBq（200mCi），9 名患者接受了串联治疗[90Y]Y-DOTATATE + [177Lu]Lu-DOTATATE，活性为 3.7GBq（50mCi + 50mCi）。在评估早期和长期并发症时，未发现所应用的治疗对肝损伤参数有显著影响。关于肝功能，PRRT 是治疗高分化或中分化、不可切除或弥漫性 NENs 患者的安全治疗方法。
